文摘
We have previously demonstrated that two prognostic features of myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML), mutant NRAS and over-expressing BCL-2, cooperate physically and functionally m>in vivom>. Screening of MDS patient bone marrow (BM) identified NRAS:BCL-2 co-localization in 64 % cases, correlating with percentage BM blasts, apoptotic features and disease status (m>pm> < 0.0001). Localization of the complex at the plasma membrane or the mitochondria correlated with disease and apoptosis features in MDS patients, whilst caspase-9 mediated mechanism was elucidated m>in vivom> and m>in vitro.m> The intensity and localization of the RAS:BCL-2 complex merits further evaluation as a novel biomarker of MDS.